公开(公告)号：US20240409653A1

公开(公告)日：2024-12-12

申请号：US18698354

申请日：2022-10-05

Applicant: GENMAB A/S ,  BIONTECH SE ,  MSD INTERNATIONAL BUSINESS GMBH

Inventor： Alexander MUIK ,  Kristina NÜRMBERGER ,  Nora PENCHEVA ,  Maria N. JURE-KUNKEL ,  Ugur SAHIN

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

Abstract: The present disclosure relates to combination therapy using a binding agent that binds to human PD-L1 and to human CD 13 7 in combination with pembrolizumab to reduce or prevent progression of a tumor or treating cancer.

公开(公告)号：US20240262924A1

公开(公告)日：2024-08-08

申请号：US18570257

申请日：2022-06-20

Applicant: GENMAB A/S ,  BioNTech SE

Inventor： Ugur SAHIN ,  Alexander MUIK ,  Ulf FORSSMANN ,  Maria N. JURE-KUNKEL ,  Gaurav BAJAJ ,  Craig THALHAUSER ,  Nora PENCHEVA

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

CPC classification number: C07K16/2878 ,  A61P35/00 ,  C07K16/2827 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/31

Abstract: The present invention relates to a method for reducing or preventing progression of a tumor or treating cancer in a subject, comprising administering to the subject a binding agent comprising a first antigen-binding region binding to human CD137, and a second antigen-binding region binding to human PD-L1. The invention further provides a binding agent for use in reducing or preventing progression of a tumor or for use in treatment of cancer.

公开(公告)号：US20250002600A1

公开(公告)日：2025-01-02

申请号：US18696689

申请日：2022-10-05

Applicant: Genmab A/S ,  BioNTech SE

Inventor： Alexander MUIK ,  Kristina SCHÖDEL ,  Nora PENCHEVA ,  Maria N. JURE-KUNKEL ,  Ugur SAHIN ,  Sina FELLERMEIER-KOPF ,  Patricia GARRIDO CASTRO ,  Jordan BLUM ,  Friederike GIESEKE ,  Esther C. W. BREIJ ,  Lars GUELEN ,  Joost NEIJSSEN ,  Karsten BECKMANN ,  Claudia PAULMANN ,  Bart-Jan DE KREUK ,  Richard G. HIBBERT ,  Janine SCHUURMAN ,  Aran LABRIJN ,  Ivan KUZMANOV

IPC: C07K16/28 ,  A61K9/00 ,  A61K39/00 ,  A61P35/00

Abstract: The present invention provides combination therapy using a binding agent that binds to human CD137 and to human PD-L1 in combination with a PD-1 inhibitor to reduce or prevent progression of a tumor or treating cancer.

公开(公告)号：US20220273809A1

公开(公告)日：2022-09-01

申请号：US17628382

申请日：2020-07-17

Applicant: GENMAB A/S

Inventor： Maarten JANMAAT ,  Nora PENCHEVA ,  Esther Cornelia Wilhelmina BREIJ ,  Julia BOSHUIZEN ,  Daniel Simon PEEPER ,  Ulf FORSSMANN ,  Tahamtan AHMADI ,  Patricia Garrido CASTRO

IPC: A61K47/68 ,  A61P35/00 ,  A61K47/02

Abstract: The present invention relates to conjugates of antibodies and cytotoxic agents for use in treatment of cancer in combination with an inhibitor of PD-1 or PD-L1. The antibodies are directed against Axl.

公开(公告)号：US20210070869A1

公开(公告)日：2021-03-11

申请号：US17046199

申请日：2019-04-10

Applicant: GENMAB A/S

Inventor： Maarten JANMAAT ,  Esther BREIJ ,  Ulf FORSSMANN ,  Tahamtan AHMADI ,  Julia BOSHUIZEN ,  Daniel PEEPER ,  Nora PENCHEVA

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00

Abstract: The disclosure relates to anti-AXL antibodies, immunoconjugates, and compositions for treatment of cancer, which is resistant to or is predicted to be or become resistant to treatment with a programmed cell death-1/programmed cell death-1 ligand (PD-1/PD-L1) inhibitor.